Acadian Asset Management’s PMV Pharmaceuticals PMVP Stock Holding History

Acadian Asset Management’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.75M	Buy	2,215,894 +200,124	+10%	+$255K	﹤0.01%	870
2025 Q4	$2.52M	Sell	2,015,770 -50,367	-2%	-$67.5K	﹤0.01%	851
2025 Q3	$2.89M	Hold	2,066,137	–	–	0.01%	798
2025 Q2	$2.19M	Buy	2,066,137 +18,960	+0.9%	+$18.6K	﹤0.01%	800
2025 Q1	$2.23M	Sell	2,047,177 -31,689	-2%	-$43K	0.01%	728
2024 Q4	$3.14M	Hold	2,078,866	–	–	0.01%	655
2024 Q3	$3.09M	Hold	2,078,866	–	–	0.01%	625
2024 Q2	$3.37M	Sell	2,078,866 -1,328	-0.1%	-$2.4K	0.01%	606
2024 Q1	$3.53M	Buy	2,080,194 +1,311,745	+171%	+$2.45M	0.01%	540
2023 Q4	$2.38M	Buy	+768,449	New	+$2.03M	0.01%	634

Other funds holding PMVP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management's PMVP Position: Q1 2026 in Review

Acadian Asset Management increased its PMV Pharmaceuticals (PMVP) stake by 9.9% in Q1 2026, buying an estimated $255K and bringing the position to 2,215,894 shares worth $2.75M. The position accounts for ﹤0.01% of the portfolio, ranked #870.

Acadian Asset Management first reported a position in PMVP in Q4 2023 and has held it in 10 quarters since. The position peaked at $3.53M in Q1 2024. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

Acadian Asset Management held 2,215,894 shares of PMV Pharmaceuticals worth $2.75M as of Q1 2026.
Acadian Asset Management bought 200,124 PMV Pharmaceuticals shares in Q1 2026, an estimated $255K.
PMV Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #870 holding.
Acadian Asset Management first reported a position in PMV Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Acadian Asset Management's PMV Pharmaceuticals position peaked at $3.53M in Q1 2024.
69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.